Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


7th International Conference on Addictive Disorders and Alcoholism

Kualalumpur, Malaysia

Gary Hulse

Gary Hulse

The University of Western Australia, Australia

Title: Improving Clinical Outcomes for Management of Heroin and Alcohol Dependence Using Sustained Release Naltrexone


Biography: Gary Hulse


Oral naltrexone has been used effectively to manage problem opiate1, and alcohol 2 use but patient noncompliance limits its utility1,2. Over the past decade an increasing body of research has suggested that the use of sustained release depot naltrexone preparations can overcome this issue and deliver improved clinical outcomes. These preparations commonly involve the use of naltrexone polymer/co-polymer base formulations administered subcutaneously or intramuscularly and depending on the formulation and mode of administration can deliver levels of blood naltrexone for between 30 to 180 days 3,4.  At the same time, research findings from pharmacogenetics  has also converged to identify variables including genetic markers and drug use history differences that play a major role in mediating the response to treatment by naltrexone5. The establishment of clinical procedures to maximise use of oral and sustained release formulations, and characterization of clinical markers to identify those patients who are most likely to benefit from naltrexone will ultimately provide significant benefit to both patients and clinicians by optimizing treatment outcome.